Current Hypertension Reports

, Volume 11, Issue 5, pp 329–336

Hypertension in patients with chronic kidney disease



Hypertension is very common in patients with chronic kidney disease (CKD); it causes early loss of kidney function and accelerated cardiovascular morbidity and mortality. African American patients with hypertension and genetic disposition are at an even higher risk for renal disease and ultimately renal failure. Hypertensive patients with CKD should aim for stringent blood pressure (BP) control (target < 130/80 mm Hg) requiring more than one drug with renin-angiotensin-aldosterone system blockade as a component of therapy targeting both hyper tension and proteinuria. Management of hypertension in the dialysis population should focus on ambulatory measurements of BP and the use of longer-acting antihypertensive drugs, with their dosage and timing adjusted according to their dialytic clearances. Hypertension is also common among kidney transplant recipients and contributes to graft loss and premature death. The target BP in transplant recipients is the same as in the CKD population, with no preference for one drug group over another. Unless contraindicated, angiotensin-converting enzyme inhibitors remain the drugs of choice for hypertension in patients with autosomal-dominant polycystic kidney disease, in whom diastolic cardiac dysfunction is a prominent feature.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Levey AS, Coresh J, Greene T, et al.; Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145:247–254.PubMedGoogle Scholar
  2. 2.
    Kidney Disease Outcomes Quality Initiative Work Group: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43(Suppl 1):S1–S290.Google Scholar
  3. 3.
    Ridao N, Luno J, Garcia de Vinuesa S, et al.: Prevalence of hypertension in renal disease. Nephrol Dial Transplant 2001, 16(Suppl 1):70–73.PubMedGoogle Scholar
  4. 4.
    Wang W, Lee ET, Fabsitz RR, et al.: A longitudinal study of hypertension risk factors and their relation to cardiovascular disease: The Strong Heart Study. Hypertension 2006, 47:403–409.PubMedCrossRefGoogle Scholar
  5. 5.
    Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206–1252.PubMedCrossRefGoogle Scholar
  6. 6.
    Perneger TV, Nieto FJ, Whelton PK, et al.: A prospective study of blood pressure and serum creatinine. Results from the “Clue” study and the ARIC study. JAMA 1993, 269:488–493.PubMedCrossRefGoogle Scholar
  7. 7.
    Fliser D, Franek E, Joest M, et al.: Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int 1997, 51:1196–1204.PubMedCrossRefGoogle Scholar
  8. 8.
    Peterson JC, Adler S, Burkart JM, et al., for the MDRD Study Group: Blood pressure control, proteinuria and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754–762.PubMedGoogle Scholar
  9. 9.
    Mallamaci F, Zuccala A, Zoccali C, et al.: The deletion polymorphism of the angiotensin-converting enzyme is associated with nephroangiosclerosis. Am J Hypertens 2000, 13:433–437.PubMedCrossRefGoogle Scholar
  10. 10.
    Appel LJ, Wright JT Jr, Greene T, et al.; African American Study of Kidney Disease and Hypertension Collaborative Research Group: Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008, 168:832–839.PubMedCrossRefGoogle Scholar
  11. 11.
    Wright JT Jr, Bakris G, Greene T, et al.; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421–2431.PubMedCrossRefGoogle Scholar
  12. 12.
    Kopp JB, Smith MW, Nelson GW, et al.: MYH9 is a majoreffect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40:1175–1184.PubMedCrossRefGoogle Scholar
  13. 13.
    Kao WH, Klag MJ, Meoni LA, et al.; Family Investigation of Nephropathy and Diabetes Research Group: MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008, 40:1185–1192.PubMedCrossRefGoogle Scholar
  14. 14.
    Freedman BI, Sedor JR: Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008, 19:2047–2051.PubMedCrossRefGoogle Scholar
  15. 15.
    De Zeeuw D, Remuzzi G, Parving HH, et al.: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309–2320.PubMedCrossRefGoogle Scholar
  16. 16.
    Ruggenenti P, Perna A, Loriga G, et al.: Blood pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multi-centre, randomised controlled trial. Lancet 2005, 365:939–946.PubMedCrossRefGoogle Scholar
  17. 17.
    Jafar TH, Stark PC, Schmid CH, et al.: Progression of kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003, 139:244–252.PubMedGoogle Scholar
  18. 18.
    Hou F, Xie D, Zhang X, et al.: Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007, 18:1889–1898.PubMedCrossRefGoogle Scholar
  19. 19.
    Arici M, Erdem Y: Dual blockade of the renin-angiotensin system for cardiorenal protection: an update. Am J Kidney Dis 2009, 53:332–345.PubMedCrossRefGoogle Scholar
  20. 20.
    Kunz R, Friedrich C, Wolbers M, et al.: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30–48.PubMedGoogle Scholar
  21. 21.
    Catapano F, Chiodini P, De Nicola L, et al.: Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008, 52:475–485.PubMedCrossRefGoogle Scholar
  22. 22.
    Bakris GL, Ruilope L, Locatelli F, et al.: Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007, 72:879–885.PubMedCrossRefGoogle Scholar
  23. 23.
    Menne J, Farsang C, Deak L, et al.: Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens 2008, 26:1860–1867.PubMedCrossRefGoogle Scholar
  24. 24.
    Mann JFE, Schmieder R, McQueen M, et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547–553.PubMedCrossRefGoogle Scholar
  25. 25.
    Navaneethan S, Nigwekar S, Sehgal A, et al.: Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. J Am Soc Nephrol 2009, 4:542–551.CrossRefGoogle Scholar
  26. 26.
    Parving HH, Persson F, Lewis JB, et al.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433–2446.PubMedCrossRefGoogle Scholar
  27. 27.
    Parving HH, Brenner BM, McMurray JJ, et al.: Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009, 24:1663–1671.PubMedCrossRefGoogle Scholar
  28. 28.
    Bakris GL, Weir MR, Secic M, et al.: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004, 65:1991–2002.PubMedCrossRefGoogle Scholar
  29. 29.
    Horl MP, Horl WH: Hemodialysis-associated hyper tension: pathophysiology and therapy. Am J Kidney Dis 2002, 39:227–244.PubMedCrossRefGoogle Scholar
  30. 30.
    Kamata T, Hishida A, Takita T, et al.: Morphologic abnormalities in the brain of chronically hemodialyzed patients without cerebrovascular disease. Am J Nephrol 2000, 20:27–31.PubMedCrossRefGoogle Scholar
  31. 31.
    Iseki K, Nakai S, Shinzato T, et al.: Prevalence and determinants of hypertension in chronic hemodialysis patients in Japan. Ther Apher Dial 2007, 11:183–188.PubMedCrossRefGoogle Scholar
  32. 32.
    Davenport A, Cox C, Thuraisingham R: Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. Kidney Int 2008, 73:759–764.PubMedCrossRefGoogle Scholar
  33. 33.
    Alborzi P, Patel N, Agarwal R: Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol 2007, 2:1228–1238.PubMedCrossRefGoogle Scholar
  34. 34.
    Agarwal R, Anderson MJ, Light RP: Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients. Am J Nephrol 2008, 28:210–217.PubMedCrossRefGoogle Scholar
  35. 35.
    Agarwal R, Light RP: Arterial stiffness and interdialytic weight gain influence ambulatory blood pressure patterns in hemodialysis patients. Am J Physiol Renal Physiol 2008, 294:F303–F308.PubMedCrossRefGoogle Scholar
  36. 36.
    Agarwal R: Antihypertensive agents and arterial stiffness: relevance to reducing cardiovascular risk in the chronic kidney disease patient. Curr Opin Nephrol Hypertens 2007, 16:409–415.PubMedGoogle Scholar
  37. 37.
    Inrig JK, Oddone EZ, Hasselblad V, et al.: Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients. Kidney Int 2007, 71:454–461.PubMedCrossRefGoogle Scholar
  38. 38.
    Li Z, Lacson E Jr, Lowrie EG, et al.: The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 2006, 48:606–615.PubMedCrossRefGoogle Scholar
  39. 39.
    Zheng S, Nath V, Coyne DW: ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. Am J Nephrol 2007, 27:522–529.PubMedCrossRefGoogle Scholar
  40. 40.
    Kasiske BL, Anjum S, Shah R, et al.: Hypertension after kidney transplantation. Am J Kidney Dis 2004, 43:1071–1081.PubMedCrossRefGoogle Scholar
  41. 41.
    Guidi E, Menghetti D, Milani S, et al.: Hypertension may be transplanted with the kidney in humans: a long-term historical prospective follow-up of recipients grafted with kidneys coming from donors with or without hypertension in their families. J Am Soc Nephrol 1996, 8:1131–1138.Google Scholar
  42. 42.
    Audard V, Matignon M, Hemery F, et al.: Risk factors and long-term outcome of transplant renal artery stenosis in adult recipients after treatment by percutaneous transluminal angioplasty. Am J Transplant 2006, 6:95–99.PubMedCrossRefGoogle Scholar
  43. 43.
    Hiremath S, Fergusson D, Doucette S: Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007, 7:2350–2360.PubMedCrossRefGoogle Scholar
  44. 44.
    Bruno S, Remuzzi G, Ruggenenti P: Transplant renal artery stenosis. J Am Soc Nephrol 2004, 15:134–141.PubMedCrossRefGoogle Scholar
  45. 45.
    Chapman AB, Johnson A, Gabow PA, et al.: The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990, 323:1091–1096.PubMedCrossRefGoogle Scholar
  46. 46.
    Oflaz H, Alisir S, Buyukaydin B, et al.: Biventricular diastolic dysfunction in patients with autosomal-dominant polycystic kidney disease. Kidney Int 2005, 68:2244–2249.PubMedCrossRefGoogle Scholar
  47. 47.
    Jafar TH, Stark PC, Schmid CH, et al.: The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 2005, 67:265–271.PubMedCrossRefGoogle Scholar
  48. 48.
    Schrier R, McFann K, Johnson A, et al.: Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 2002, 13:1733–1739.PubMedCrossRefGoogle Scholar
  49. 49.
    Kidney Disease Outcomes Quality Initiative Work Group: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Executive summary. Am J Kidney Dis 2004, 43(Suppl 1):S16–S33.Google Scholar
  50. 50.
    Kidney Disease Outcomes Quality Initiative Work Group: K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005, 45:S49–S57.CrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Nephrology DivisionBaylor University Medical CenterDallasUSA

Personalised recommendations